Combined nasal medications are an efficient therapy for enhancing the symptoms of many respiratory disorders such as allergic rhinitis. The manifestations of rhinitis have been receiving more attention because of the potential for overlapping or misunderstanding between allergic rhinitis symptoms and those of coronavirus disease 2019 (COVID-19). Azelastine hydrochloride (AZH) and fluticasone propionate (FLU) are among the most effective drug combinations for elevating the symptoms of allergic rhinitis. To promote and make it easier for various researchers to get literature reviews for their studies on the drugs being mentioned, different analytical methods have been collected and discussed in this mini-review for the quantitative assay of AZH and FLU in their pharmaceutical formulation and different biological fluids. The assembled approaches include pharmacopeial, chromatographic (HPLC, CE, and TLC), spectroscopic (spectrophotometric and spectrofluorimetric), and electrochemical methods. In accordance with the findings of this study, AZH was determined either alone or with its genotoxic impurity, major metabolite, and alkaline degradant in different matrices using various analytical methods. Moreover, HPLC technique made it possible to analyze FLU along with its major metabolite in human plasma. In addition, the pharmaceutical formulation was the applicable matrix for the simultaneous analysis of AZH and FLU. The data provided in this study can be used to successfully perform additional research for the quantitative analysis of AZH and FLU.